Triple targeting of HER receptors overcomes heregulin-mediated resistance to EGFR blockade in colorectal cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-21-0818
Abstract: Current treatment options for patients with advanced colorectal cancers (CRC) include anti-EGFR/HER1 therapy with the blocking antibody cetuximab. Although a subset of patients with KRAS wild-type disease initially respond to the treatment, resistance develops in… read more here.
Keywords: kras wild; triple targeting; resistance; egfr ... See more keywords